BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units covering an aggregate of 89,750 shares, of BioCryst common stock. The options and RSUs were granted as of August 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves
- BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating
- BioCryst Pharmaceuticals Reports Record Q2 2025 Results
- BioCryst’s Strong Q2 Performance and Unique Market Position Justify Buy Rating
- BioCryst’s Strong Performance and Growth Potential Justifies Buy Rating